Equillium, Inc.

DB:0FY Stock Report

Market Cap: €26.6m

Equillium Valuation

Is 0FY undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0FY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 0FY's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 0FY's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0FY?

Key metric: As 0FY is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0FY. This is calculated by dividing 0FY's market cap by their current revenue.
What is 0FY's PS Ratio?
PS Ratio0.6x
SalesUS$45.91m
Market CapUS$27.43m

Price to Sales Ratio vs Peers

How does 0FY's PS Ratio compare to its peers?

The above table shows the PS ratio for 0FY vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average6.2x
2INV 2invest
8.7xn/a€67.3m
CNW co.don
0.7xn/a€6.5m
MDG1 Medigene
2.1x16.4%€15.6m
HPHA Heidelberg Pharma
13.4x16.6%€113.3m
0FY Equillium
0.6x21.2%€27.4m

Price-To-Sales vs Peers: 0FY is good value based on its Price-To-Sales Ratio (0.6x) compared to the peer average (8x).

Price to Sales Ratio vs Industry

How does 0FY's PS Ratio compare vs other companies in the DE Biotechs Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.8.1x19.8%
0FY Equillium
 0.6x21.2%US$27.43m
CNW co.don
0.7xn/aUS$6.97m
V9Z Aceragen
0.4xn/aUS$3.12m
0FY 0.6xIndustry Avg. 8.1xNo. of Companies5PS0612182430+
6 CompaniesEstimated GrowthMarket Cap
Industry Avg.8.1x34.6%
0FY Equillium
 0.6x-22.3%US$27.43m
No more companies

Price-To-Sales vs Industry: 0FY is good value based on its Price-To-Sales Ratio (0.6x) compared to the European Biotechs industry average (8x).

Price to Sales Ratio vs Fair Ratio

What is 0FY's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0FY PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.6x
Fair PS Ratio2.9x

Price-To-Sales vs Fair Ratio: 0FY is good value based on its Price-To-Sales Ratio (0.6x) compared to the estimated Fair Price-To-Sales Ratio (2.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0FY forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€0.71
€3.17
+344.1%
37.4%€4.76€1.90n/a3
Jan ’26€0.63
€3.17
+404.1%
37.4%€4.76€1.90n/a3
Dec ’25€0.72
€3.17
+337.3%
37.4%€4.76€1.90n/a3
Nov ’25€1.16
€3.08
+165.2%
37.4%€4.61€1.85n/a3
Oct ’25€0.70
€6.18
+776.3%
16.1%€7.32€4.58n/a4
Sep ’25€0.93
€6.18
+565.0%
16.1%€7.32€4.58n/a4
Aug ’25€0.66
€6.21
+846.2%
16.1%€7.36€4.60n/a4
Jul ’25€0.60
€6.21
+941.5%
16.1%€7.36€4.60n/a4
Jun ’25€1.30
€6.21
+379.0%
16.1%€7.36€4.60n/a4
May ’25€1.53
€6.27
+310.8%
16.1%€7.43€4.64n/a4
Apr ’25€1.93
€6.00
+211.3%
23.1%€7.39€3.69n/a4
Mar ’25€2.34
€5.43
+132.7%
23.6%€6.34€3.62n/a3
Feb ’25€0.74
€5.43
+629.3%
23.6%€6.34€3.62n/a3
Jan ’25€0.58
€5.43
+835.2%
23.6%€6.34€3.62€0.633
Dec ’24€0.50
€5.69
+1,028.0%
19.1%€6.45€4.15€0.723
Nov ’24€0.45
€6.51
+1,334.7%
13.0%€7.57€5.21€1.164
Oct ’24€0.68
€5.58
+727.2%
30.0%€7.37€2.58€0.705
Sep ’24€0.74
€5.58
+657.6%
30.0%€7.37€2.58€0.935
Aug ’24€0.66
€5.58
+742.2%
30.0%€7.37€2.58€0.665
Jul ’24€0.68
€5.58
+727.2%
30.0%€7.37€2.58€0.605
Jun ’24€0.56
€5.58
+888.3%
30.0%€7.37€2.58€1.305
May ’24€0.56
€5.89
+959.0%
36.3%€9.12€2.55€1.535
Apr ’24€0.65
€8.70
+1,236.3%
61.9%€18.59€2.60€1.935
Mar ’24€0.85
€9.93
+1,066.4%
51.2%€18.73€3.75€2.345
Feb ’24€0.97
€11.54
+1,083.3%
47.1%€19.23€3.85€0.744
Jan ’24€0.81
€11.54
+1,324.3%
47.1%€19.23€3.85€0.584
Analyst Price Target
Consensus Narrative from 3 Analysts
€3.32
Fair Value
78.5% undervalued intrinsic discount
3
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/08 07:27
End of Day Share Price 2025/01/08 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Equillium, Inc. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Lut Ming ChengCantor Fitzgerald & Co.
Raghuram SelvarajuH.C. Wainwright & Co.
Biren AminJefferies LLC